Eli Lilly and Company (LLY)
Eli Lilly and Company (LLY) is a healthcare company (drug manufacturers - general) based in the United States. The share price is $1,415.55, down 1.13% on the day, which values the company at $1.26T. Price as of 17 Nov 2026, 17:10 UTC, from Yahoo Finance.
Key facts
- Share price
- $1,415.55−1.13% today
- Market value
- $1.26T
- P/E ratio
- 45.9×last 12 months
- Forward P/E
- 27.9×
- Dividend yield
- 0.47%
- Funk Score
- 70/100
- Against its own history
- Well above its usual priceusual price $324.25
- 200-week average
- $802.9276% above
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Eli Lilly and Company in more detail
LLY trades at 45.9× its last twelve months' earnings, 27.9× next year's expected earnings, 14.6× sales. Measured against its own history, the price is 337% above what its usual multiples would imply ($324.25) — well above its usual price. It sits 76% above its 200-week average of $802.92.
Over the last five fiscal years Eli Lilly and Company has compounded revenue 21.6% a year, earnings per share 27.6% a year. Its Funk Score is 70 out of 100 (financial strength 6.8, profitability 8.6, growth 10.0, value 2.7, each out of 10).
In its favour: Altman Z in the safe zone; Strong Piotroski score.
28 of the superinvestors tracked here hold LLY, including Primecap team (6.5% of the portfolio), Polen Capital team (4.6% of the portfolio), Jensen team (4.0% of the portfolio).
Superinvestors holding LLY
28 of the investors tracked here report a position in their latest 13F filing.
- Primecap team Primecap Management6.52% of portfolio · $10.5B · trimmed · Q3 2026
- Polen Capital team Polen Capital Management4.64% of portfolio · $427.4M · trimmed · Q3 2026
- Jensen team Jensen Investment Management4.00% of portfolio · $127.6M · trimmed · Q3 2026
- Mairs & Power team Mairs & Power3.35% of portfolio · $365.3M · trimmed · Q3 2026
- Jeremy Grantham (co-founder) GMO (Grantham, Mayo, Van Otterloo)1.87% of portfolio · $872.4M · added · Q3 2026
- Ken Fisher Fisher Investments1.80% of portfolio · $6.3B · added · Q3 2026
- Rajiv Jain GQG Partners1.65% of portfolio · $878.1M · new · Q3 2026
- Larry Robbins Glenview Capital Management1.38% of portfolio · $69.3M · new · Q2 2026
- Cathie Wood ARK Invest0.72% of portfolio · $124.8M · added · Q3 2026
- Ken Griffin Citadel Advisors0.65% of portfolio · $1.1B · added · Q2 2026
- Jeffrey Altman Owl Creek Asset Management0.56% of portfolio · $4.2M · new · Q3 2026
- Temasek Temasek Holdings0.50% of portfolio · $180.1M · added · Q3 2026
- Brandon Haley Holocene Advisors0.49% of portfolio · $211.7M · trimmed · Q2 2026
- Cliff Asness AQR Capital Management0.43% of portfolio · $1.2B · added · Q2 2026
- Ray Dalio (founder) Bridgewater Associates0.43% of portfolio · $104.4M · added · Q2 2026
- George Soros Soros Fund Management0.40% of portfolio · $25.7M · Q3 2026
- David Shaw (founder) D. E. Shaw & Co.0.37% of portfolio · $595.6M · trimmed · Q2 2026
- Stanley Druckenmiller Duquesne Family Office0.34% of portfolio · $14.8M · new · Q2 2026
- Mario Gabelli GAMCO Investors0.31% of portfolio · $31.3M · trimmed · Q3 2026
- John Overdeck and David Siegel (founders) Two Sigma Investments0.29% of portfolio · $392.5M · added · Q3 2026
- Frank Sands Sands Capital Management0.20% of portfolio · $48.8M · trimmed · Q3 2026
- Ron Baron Baron Capital (BAMCO)0.18% of portfolio · $105.7M · trimmed · Q3 2026
- Paul Tudor Jones Tudor Investment Corp0.15% of portfolio · $37M · trimmed · Q2 2026
- Israel Englander Millennium Management0.15% of portfolio · $219.1M · trimmed · Q2 2026
- Rob Citrone Discovery Capital Management0.11% of portfolio · $2.7M · new · Q2 2026
- Murray Stahl Horizon Kinetics0.05% of portfolio · $4.1M · trimmed · Q3 2026
- Dodge & Cox team Dodge & Cox0.03% of portfolio · $46.3M · trimmed · Q3 2026
- Bill Nygren Harris Associates (Oakmark)0.00% of portfolio · $517K · trimmed · Q2 2026
Health Care companies of similar size
- Johnson & JohnsonJNJ
- AbbVieABBV
- Merck & CoMRK
- UnitedHealth GroupUNH
- NovartisNVS
- AstraZenecaAZN
- Thermo Fisher ScientificTMO
- AmgenAMGN
- Gilead SciencesGILD
- Abbott LaboratoriesABT
- Novo NordiskNVO
- PfizerPFE
Side by side:LLY vs JNJ (Eli Lilly and Company vs Johnson & Johnson)LLY vs ABBV (Eli Lilly and Company vs AbbVie)LLY vs MRK (Eli Lilly and Company vs Merck & Co)LLY vs UNH (Eli Lilly and Company vs UnitedHealth Group)LLY vs NVS (Eli Lilly and Company vs Novartis)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Eli Lilly and Company (LLY): questions and answers
What is LLY's P/E ratio?
Eli Lilly and Company trades at 45.9× its last twelve months' earnings and 27.9× next year's expected earnings. At its fiscal year-ends over the past 16 years the P/E ranged from 7.7× to 100.5×, with a median of 29.7×.
What is LLY's PEG ratio?
Eli Lilly and Company's PEG ratio is 1.33 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Eli Lilly and Company's market cap?
Eli Lilly and Company is valued at $1.26T at a share price of $1,415.55.
Is LLY overvalued or undervalued?
Against its own history, LLY is well above its usual price: the price is 337% above the $324.25 implied by the median multiples it has traded at (price / earnings, price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is LLY above its 200-week moving average?
Yes. LLY is 76.3% above its 200-week average of $802.92. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Eli Lilly and Company growing?
Over the last five fiscal years Eli Lilly and Company's revenue grew 21.6% a year and its earnings per share 27.6% a year; over ten years revenue grew 12.6% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Eli Lilly and Company (LLY) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/LLY
Underlying data: Yahoo Finance; company filings with the SEC.